June 10, 2021.
Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has completed a successful and fully subscribed unit offering bringing the company
SEK 50 million and that Biosergen’s share will be listed on Nasdaq First North Growth Market in
Stockholm on
June 24, 2021. The proceeds from the offering allow Biosergen to launch clinical trials of its antifungal drug candidate BSG005 with the ambition of filing for market approval in
the United States and
Europe by the end of 2025.
Biosergen develops BSG005, an antifungal drug candidate which has demonstrated a wide spectrum of antimycotic effects in several preclinical experimental models. To date, fungal infections cause more than 1.5 million deaths annually around the world, derived from systemic infections occurring in both natural environments and in hospitals. By addressing the sizeable need for new and effective antifungals, Biosergen is targeting a market with
United-states
Sweden
Stockholm
Karolinska-institutet
Johan-dighed
Viktor-drvota
Eu-press
Karolinska-development-ab-nasdaq-stockholm
Karolinska-development
Nasdaq-stockholm
Nasdaq-first-north-growth-market
Nasdaq-first-growth-market